Table of Contents
ISRN Gastroenterology
Volume 2013, Article ID 179024, 5 pages
http://dx.doi.org/10.1155/2013/179024
Clinical Study

Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis

1Children's Hospital, Helsinki University Central Hospital, P.O. Box 281, 00029 Helsinki, Finland
2Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, P.O. Box 3235, Jerusalem 91031, Israel

Received 5 January 2013; Accepted 29 January 2013

Academic Editors: A. Amedei, A. W. Mangel, J. M. Pajares, L. Rodrigo, A. A. te Velde, and A. Weimann

Copyright © 2013 Kaija-Leena Kolho and Dan Turner. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. K. Bunn, W. M. Bisset, M. J. C. Main, and B. E. Golden, “Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 32, no. 2, pp. 171–177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Bunn, W. M. Bisset, M. J. C. Main, E. S. Gray, S. Olson, and B. E. Golden, “Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no. 1, pp. 14–22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. R. B. Canani, G. Terrin, L. Rapacciuolo et al., “Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease,” Digestive and Liver Disease, vol. 40, no. 7, pp. 547–553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Diamanti, F. Colistro, M. S. Basso et al., “Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 14, no. 9, pp. 1229–1235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Canani, L. Rapacciuolo, M. T. Romano et al., “Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice,” Digestive and Liver Disease, vol. 36, no. 7, pp. 467–470, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. R. Walker, M. L. Land, A. Kartashov et al., “Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 44, no. 4, pp. 414–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Aomatsu, A. Yoden, K. Matsumoto et al., “Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 56, no. 8, pp. 2372–2377, 2011. View at Publisher · View at Google Scholar
  8. P. Henderson, A. Casey, S. J. Lawrence et al., “The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 107, no. 6, pp. 941–949, 2012. View at Publisher · View at Google Scholar
  9. T. Sipponen and K. L. Kolho, “Faecal calprotectin in children with clinically quiescent inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 45, no. 7-8, pp. 872–877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Turner, C. H. Seow, G. R. Greenberg, A. M. Griffiths, M. S. Silverberg, and A. H. Steinhart, “A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1081–1088, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gustavsson, G. Järnerot, E. Hertervig et al., “Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 8, pp. 984–989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Turner, D. Mack, N. Leleiko et al., “Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response,” Gastroenterology, vol. 138, no. 7, pp. 2282–2291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Kolho, T. Raivio, H. Lindahl, and E. Savilahti, “Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 41, no. 6, pp. 720–725, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Hämäläinen, T. Sipponen, and K.-L. Kolho, “Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels,” World Journal of Gastroenterology, vol. 17, pp. 5166–5171, 2011. View at Google Scholar
  15. D. Turner, A. R. Otley, D. Mack et al., “Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study,” Gastroenterology, vol. 133, no. 2, pp. 423–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Turner, J. Hyams, J. Markowitz et al., “Appraisal of the pediatric ulcerative colitis activity index (PUCAI),” Inflammatory Bowel Diseases, vol. 15, no. 8, pp. 1218–1223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Turner, C. H. Seow, G. R. Greenberg, A. M. Griffiths, M. S. Silverberg, and A. H. Steinhart, “A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1081–1088, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Turner, S. T. Leach, D. Mack et al., “Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response,” Gut, vol. 59, no. 9, pp. 1207–1212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. T. Ho, H. M. Lee, G. Brydon et al., “Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis,” American Journal of Gastroenterology, vol. 104, no. 3, pp. 673–678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. E. Lennard-Jones, “Classification of inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, Supplement, vol. 24, no. 170, pp. 2–6, 1989. View at Google Scholar · View at Scopus
  21. K. L. Kolho, H. Alfthan, and E. Hämäläinen, “Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients,” Journal of Pediatric Gastroenterology and Nutrition, vol. 55, no. 6, pp. 751–753, 2012. View at Publisher · View at Google Scholar
  22. J. F. Colombel, P. Rutgeerts, W. Reinisch et al., “Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis,” Gastroenterology, vol. 141, no. 4, pp. 1194–1201, 2011. View at Publisher · View at Google Scholar
  23. K. F. Frøslie, J. Jahnsen, B. A. Moum, and M. H. Vatn, “Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort,” Gastroenterology, vol. 133, no. 2, pp. 412–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Turner, C. M. Walsh, E. I. Benchimol et al., “Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy,” Gut, vol. 57, no. 3, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Shaoul, M. Sladek, D. Turner et al., “Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease,” Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1493–1497, 2012. View at Publisher · View at Google Scholar